Regarding DFS, AML patients with high CEBPA gene expression had a cumulative DFS at 6 months 87.8%, while patients with low CEBPA gene expression had a cumulative DFS at 6 months of 8.5%, with statistically significant difference encountered between the two patients group with P <0.001. This evidence concerns the gene CEBPA and acute myeloid leukemia.